Global Ganja Report

When the United Kingdom announced the historic step of rescheduling cannabis and allowing physicians to prescribe it two months ago, there was concern from patients and advocates as to whether actual herbaceous flower would be allowed, or only extracts. Now the first patient is approved to receive cannabis under the program, and it is indeed to be dried flower. The bad news: with the National Health Service barred by bureaucratic hurdles from providing it, patients are at the mercy of the market—and the price is prohibitive. 

While Canada's move to officially legalize cannabis has been hailed as courageous and historic by advocates around the world, some of the planet's most intolerant governments are reacting with dismay—even threatening to have their own citizens arrested if they indulge in legal marijuana on Canadian sovereign territory.

Physicians in the United Kingdom will be able to legally prescribe medical marijuana products to their patients starting next month. The policy shift follows a public outcry over cases of young epileptic patients who were denied the only treatments that worked for them. 

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

The British government has finally capitulated to pressure from patients, activists and even regional authorities, and officially pledged to make medical cannabis products available on prescription this year. But it remains to be seen which products will win approval—and actual herbaceous cannabis is unlikely to make the cut.

In another sign of turning tides, a prestigious British think-tank once beloved of Margaret Thatcher has called on the government to legalize cannabis. The breakthrough report finds that a legal cannabis industry could raise £1 billion per year in tax revenues for the United Kingdom, while undercutting the black market.

With Canada now joining Uruguay as the second country to legalize cannabis at the national level, industry eyes are scanning the world map for which could be the likely third. Latin America may provide the candidate, as even UN experts now urge the region's governments to consider legalization as a way out of the endemic narco-violence. But pressure for legal cannabis is fast mounting in several European countries as well. Legalization may soon be on the legislative agenda in Australia, while New Zealand has promised to put the questions before the voters. 

Something of a corporate scramble is underway to secure patents for the various curative properties of CBD, and associated products and procedures. Pharmaceutical firms see a windfall, but some activists raise concerns about the creeping privatization of a cannabinoid that should belong to the genetic and intellectual commons of the human race. How realistic are fears about the imminent arrival of "corporate cannabis"?